Skip to main content
Premium Trial:

Request an Annual Quote

Purigen Biosystems Gets CE Mark for Nucleic Acid Isolation System

NEW YORK — Purigen Biosystems said on Tuesday that it has received the CE mark for its Ionic Purification System for nucleic acid isolation.

Launched in the US in 2019, the benchtop system uses isotachophoresis to extract, purify, and concentrate genomic RNA and DNA from cells and formalin-fixed, paraffin-embedded tissues.

"Over the past year, we have seen increasing interest in our innovative Ionic Purification System from around the world, especially in the UK and European Union," Purigen CEO Barney Saunders said in a statement. "Our team was able to quickly shift priorities to secure the appropriate regulatory approvals, which has enabled us to expand our commercial operations."

The Pleasanton, California-based company, which was spun out of Stanford University in 2012, said it is in the process of expanding its commercial operations to meet growing demand for the Ionic system.

Purigen also said that researchers at the Centre for Environment Fisheries and Aquaculture Science in the UK intend to use the system to study diseases of commercially cultured and harvested fish and shellfish, as well as microbial risks to human health from shellfish and other aquatic sources.

In late 2020, the firm was also named as a finalist in Xprize's $6 million rapid COVID-19 testing competition.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.